Exosomes Show Promise as Targeted Delivery System for Skin Cancer Immunotherapy

Skin cancer remains one of the most diagnosed cancers worldwide, with metastatic progression being the primary cause of death. Current treatments including surgery, radiation, chemotherapy, and immunotherapy have improved survival but are limited by severe side effects and treatment resistance.

This comprehensive review examined exosome-based therapeutic strategies for skin cancer treatment. Exosomes are naturally occurring extracellular vesicles that can serve as biological nanocarriers, delivering therapeutic agents directly to cancer cells. The researchers analyzed preclinical and early clinical studies investigating exosome-mediated delivery of chemotherapy drugs, nucleic acids, and immune modulators.

The evidence reveals that exosome-based delivery systems offer several advantages over conventional treatments. They demonstrate improved tumor specificity, enhanced drug bioavailability, reduced systemic toxicity, and ability to overcome both immune and chemotherapy resistance mechanisms. These vesicles can modify the tumor microenvironment and enhance immunotherapy effectiveness.

For longevity and health optimization, this research represents a paradigm shift toward precision medicine approaches that could dramatically improve cancer outcomes while preserving quality of life. The targeted nature of exosome therapy could reduce the devastating side effects that often accompany traditional cancer treatments, allowing patients to maintain better health during and after treatment.

However, this review synthesizes existing research rather than presenting new clinical data. Most evidence comes from preclinical studies, and more human trials are needed to establish safety and efficacy. The technology also faces manufacturing and regulatory challenges before widespread clinical implementation becomes possible.